Medical - Care Facilities
Compare Stocks
2 / 10Stock Comparison
JYNT vs USPH
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Care Facilities
JYNT vs USPH — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Care Facilities | Medical - Care Facilities |
| Market Cap | $124M | $897M |
| Revenue (TTM) | $57M | $695M |
| Net Income (TTM) | $3M | $11M |
| Gross Margin | 78.5% | 22.0% |
| Operating Margin | 1.1% | 12.2% |
| Forward P/E | 44.9x | 20.6x |
| Total Debt | $2M | $426M |
| Cash & Equiv. | $24M | $36M |
JYNT vs USPH — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| The Joint Corp. (JYNT) | 100 | 57.4 | -42.6% |
| U.S. Physical Thera… (USPH) | 100 | 79.6 | -20.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: JYNT vs USPH
Each card shows where this stock fits in a portfolio — not just who wins on paper.
JYNT is the clearest fit if your priority is long-term compounding and sleep-well-at-night.
- 191.9% 10Y total return vs USPH's 22.6%
- Lower volatility, beta 0.98, Low D/E 13.3%, current ratio 1.59x
- 5.7% margin vs USPH's 1.5%
USPH carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 5 yrs, beta 0.93, yield 3.1%
- Rev growth 16.3%, EPS growth -22.8%, 3Y rev CAGR 12.2%
- Beta 0.93, yield 3.1%, current ratio 1.01x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 16.3% revenue growth vs JYNT's 5.2% | |
| Value | Lower P/E (20.6x vs 44.9x) | |
| Quality / Margins | 5.7% margin vs USPH's 1.5% | |
| Stability / Safety | Beta 0.93 vs JYNT's 0.98 | |
| Dividends | 3.1% yield; 5-year raise streak; the other pay no meaningful dividend | |
| Momentum (1Y) | -12.8% vs USPH's -14.3% | |
| Efficiency (ROA) | 5.0% ROA vs USPH's 0.9% |
JYNT vs USPH — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
JYNT vs USPH — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
JYNT leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
USPH is the larger business by revenue, generating $695M annually — 12.3x JYNT's $57M. Profitability is closely matched — net margins range from 5.7% (JYNT) to 1.5% (USPH). On growth, JYNT holds the edge at +13.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $57M | $695M |
| EBITDAEarnings before interest/tax | $2M | $107M |
| Net IncomeAfter-tax profit | $3M | $11M |
| Free Cash FlowCash after capex | $3M | $67M |
| Gross MarginGross profit ÷ Revenue | +78.5% | +22.0% |
| Operating MarginEBIT ÷ Revenue | +1.1% | +12.2% |
| Net MarginNet income ÷ Revenue | +5.7% | +1.5% |
| FCF MarginFCF ÷ Revenue | +4.7% | +9.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | +13.3% | +7.7% |
| EPS Growth (YoY)Latest quarter vs prior year | +71.4% | -115.0% |
Valuation Metrics
USPH leads this category, winning 6 of 6 comparable metrics.
Valuation Metrics
At 41.5x trailing earnings, USPH trades at a 9% valuation discount to JYNT's 45.6x P/E. On an enterprise value basis, USPH's 12.5x EV/EBITDA is more attractive than JYNT's 126.9x.
| Metric | ||
|---|---|---|
| Market CapShares × price | $124M | $897M |
| Enterprise ValueMkt cap + debt − cash | $103M | $1.3B |
| Trailing P/EPrice ÷ TTM EPS | 45.63x | 41.55x |
| Forward P/EPrice ÷ next-FY EPS est. | 44.85x | 20.63x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 126.93x | 12.52x |
| Price / SalesMarket cap ÷ Revenue | 2.26x | 1.15x |
| Price / BookPrice ÷ Book value/share | 8.70x | 1.16x |
| Price / FCFMarket cap ÷ FCF | 370.99x | 14.71x |
Profitability & Efficiency
JYNT leads this category, winning 6 of 7 comparable metrics.
Profitability & Efficiency
JYNT delivers a 16.9% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $1 for USPH. JYNT carries lower financial leverage with a 0.13x debt-to-equity ratio, signaling a more conservative balance sheet compared to USPH's 0.55x. On the Piotroski fundamental quality scale (0–9), JYNT scores 6/9 vs USPH's 5/9, reflecting solid financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | +16.9% | +1.4% |
| ROA (TTM)Return on assets | +5.0% | +0.9% |
| ROICReturn on invested capital | — | +5.6% |
| ROCEReturn on capital employed | -2.9% | +7.6% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 5 |
| Debt / EquityFinancial leverage | 0.13x | 0.55x |
| Net DebtTotal debt minus cash | -$22M | $390M |
| Cash & Equiv.Liquid assets | $24M | $36M |
| Total DebtShort + long-term debt | $2M | $426M |
| Interest CoverageEBIT ÷ Interest expense | — | 15.42x |
Total Returns (Dividends Reinvested)
JYNT leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in USPH five years ago would be worth $5,664 today (with dividends reinvested), compared to $1,608 for JYNT. Over the past 12 months, JYNT leads with a -12.8% total return vs USPH's -14.3%. The 3-year compound annual growth rate (CAGR) favors JYNT at -16.1% vs USPH's -17.4% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -2.0% | -24.6% |
| 1-Year ReturnPast 12 months | -12.8% | -14.3% |
| 3-Year ReturnCumulative with dividends | -41.0% | -43.7% |
| 5-Year ReturnCumulative with dividends | -83.9% | -43.4% |
| 10-Year ReturnCumulative with dividends | +191.9% | +22.6% |
| CAGR (3Y)Annualised 3-year return | -16.1% | -17.4% |
Risk & Volatility
Evenly matched — JYNT and USPH each lead in 1 of 2 comparable metrics.
Risk & Volatility
USPH is the less volatile stock with a 0.93 beta — it tends to amplify market swings less than JYNT's 0.98 beta. A beta below 1.0 means the stock typically moves less than the S&P 500.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.98x | 0.93x |
| 52-Week HighHighest price in past year | $13.47 | $93.50 |
| 52-Week LowLowest price in past year | $7.50 | $58.55 |
| % of 52W HighCurrent price vs 52-week peak | +64.4% | +63.1% |
| RSI (14)Momentum oscillator 0–100 | 49.3 | 46.1 |
| Avg Volume (50D)Average daily shares traded | 57K | 171K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates JYNT as "Buy" and USPH as "Buy". Consensus price targets imply 130.7% upside for JYNT (target: $20) vs 72.9% for USPH (target: $102). USPH is the only dividend payer here at 3.06% yield — a key consideration for income-focused portfolios.
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $20.00 | $102.00 |
| # AnalystsCovering analysts | 8 | 12 |
| Dividend YieldAnnual dividend ÷ price | — | +3.1% |
| Dividend StreakConsecutive years of raises | — | 5 |
| Dividend / ShareAnnual DPS | — | $1.80 |
| Buyback YieldShare repurchases ÷ mkt cap | +9.1% | +0.6% |
JYNT leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). USPH leads in 1 (Valuation Metrics). 1 tied.
JYNT vs USPH: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is JYNT or USPH a better buy right now?
For growth investors, U.
S. Physical Therapy, Inc. (USPH) is the stronger pick with 16. 3% revenue growth year-over-year, versus 5. 2% for The Joint Corp. (JYNT). U. S. Physical Therapy, Inc. (USPH) offers the better valuation at 41. 5x trailing P/E (20. 6x forward), making it the more compelling value choice. Analysts rate The Joint Corp. (JYNT) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — JYNT or USPH?
On trailing P/E, U.
S. Physical Therapy, Inc. (USPH) is the cheapest at 41. 5x versus The Joint Corp. at 45. 6x. On forward P/E, U. S. Physical Therapy, Inc. is actually cheaper at 20. 6x.
03Which is the better long-term investment — JYNT or USPH?
Over the past 5 years, U.
S. Physical Therapy, Inc. (USPH) delivered a total return of -43. 4%, compared to -83. 9% for The Joint Corp. (JYNT). Over 10 years, the gap is even starker: JYNT returned +191. 9% versus USPH's +22. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — JYNT or USPH?
By beta (market sensitivity over 5 years), U.
S. Physical Therapy, Inc. (USPH) is the lower-risk stock at 0. 93β versus The Joint Corp. 's 0. 98β — meaning JYNT is approximately 6% more volatile than USPH relative to the S&P 500. On balance sheet safety, The Joint Corp. (JYNT) carries a lower debt/equity ratio of 13% versus 55% for U. S. Physical Therapy, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — JYNT or USPH?
By revenue growth (latest reported year), U.
S. Physical Therapy, Inc. (USPH) is pulling ahead at 16. 3% versus 5. 2% for The Joint Corp. (JYNT). On earnings-per-share growth, the picture is similar: The Joint Corp. grew EPS 133. 9% year-over-year, compared to -22. 8% for U. S. Physical Therapy, Inc.. Over a 3-year CAGR, USPH leads at 12. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — JYNT or USPH?
The Joint Corp.
(JYNT) is the more profitable company, earning 5. 3% net margin versus 1. 9% for U. S. Physical Therapy, Inc. — meaning it keeps 5. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: USPH leads at 10. 3% versus -1. 6% for JYNT. At the gross margin level — before operating expenses — JYNT leads at 76. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is JYNT or USPH more undervalued right now?
On forward earnings alone, U.
S. Physical Therapy, Inc. (USPH) trades at 20. 6x forward P/E versus 44. 9x for The Joint Corp. — 24. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for JYNT: 130. 7% to $20. 00.
08Which pays a better dividend — JYNT or USPH?
In this comparison, USPH (3.
1% yield) pays a dividend. JYNT does not pay a meaningful dividend and should not be held primarily for income.
09Is JYNT or USPH better for a retirement portfolio?
For long-horizon retirement investors, U.
S. Physical Therapy, Inc. (USPH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 93), 3. 1% yield). Both have compounded well over 10 years (USPH: +22. 6%, JYNT: +191. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between JYNT and USPH?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: JYNT is a small-cap quality compounder stock; USPH is a small-cap high-growth stock. USPH pays a dividend while JYNT does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.